Table 1 Patient Demographic and Clinical Characteristics
From: Symptoms and impacts in anemia of chronic kidney disease
Wave 1 CE Interviews (n = 14) | Wave 2 Combined CE/CD Interviews (n = 14) | Wave 3 CD Interviews (n = 8) | All Participants (n = 36) | |
|---|---|---|---|---|
Age, years, mean ± SD (range) | 65 ± 17.6 (30–83) | 55 ± 15.8 (32–82) | 71.4 ± 14.6 (48–88) | 62.7 ± 17.1 (30–88) |
Gender, n (%) | ||||
Male | 4 (29) | 3 (21) | 3 (38) | 10 (28) |
Female | 10 (71) | 11 (79) | 5 (62) | 26 (72) |
Race/Ethnicity, n (%) | ||||
White | 7 (50) | 2 (14) | 0 | 9 (25) |
Black | 5 (36) | 9 (64) | 8 (100) | 22 (61) |
Hispanic | 2 (14) | 3 (21) | 0 | 5 (14) |
Education | ||||
Less than HS | 0 | 2 (14) | 0 | 2 (6) |
HS diploma | 4 (29) | 4 (29) | 1 (13) | 9 (25) |
Some college | 10 (71) | 6 (43) | 5 (63) | 21 (58) |
College degree | 0 | 2 (14) | 1 (13) | 3 (8) |
Professional or advanced degree | 0 | 0 | 1 (13) | 1 (3) |
CKD stage, n (%) | ||||
Stage 3a | 1 (7) | 0 | 0 | 1 (3) |
Stage 3b | 2 (14) | 1 (7) | 3 (38) | 6 (17) |
Stage 4 | 3 (21) | 5 (36) | 2 (25) | 10 (28) |
Stage 5 (not on dialysis) | 0 | 0 | 2 (25) | 2 (6) |
Stage 5 (on dialysis) | 8 (57) | 8 (57) | 1 (13) | 17 (47) |
Comorbid conditions, n (%) | ||||
Myocardial infarction | 1 (7) | 2 (14) | 0 | 3 (8) |
Stroke/transient ischemic attack | 0 | 1 (7) | 1 (13) | 1 (6) |
Arterial hypertension | 7 (50) | 6 (43) | 8 (100) | 21 (58) |
Diabetes mellitus | 5 (36) | 6 (43) | 4 (50) | 15 (42) |
Cardiovascular disease | 1 (7) | 0 | 1 (4) | 5 (14) |
Congestive heart failure | 2 (14) | 7 (50) | 2 (25) | 11 (31) |
Lung disease | 2 (14) | 3 (21) | 0 | 5 (14) |
Receiving dialysis, n (%) | ||||
Hemodialysis | 5 (36) | 8 (57) | 1 (13) | 14 (39) |
Peritoneal dialysis | 3 (21) | 3 (21) | 0 | 6 (17) |
No | 6 (43) | 3 (21) | 7 (87) | 16 (44) |
Treatment with ESA, n (%) | ||||
Yes | 11 (79) | 12 (86) | 2 (25) | 25 (69) |
No | 3 (21) | 2 (14) | 6 (75) | 11 (31) |
Hemoglobin, mean ± SD (range, g/dL) | 9.8 ± 0.9 (8.7–11.5) | 9.5 ± 0.9 (7.2–10.4) | 9.1 ± 0.7 (8.0–9.7) | 9.5 ± 0.9 (7.2–11.5) |
Iron treatment, n (%) | ||||
Intravenous | 6 (43) | 8 (57) | 1 (12) | 15 (42) |
Oral | 3 (21) | 2 (14) | 7 (88) | 5 (14) |